Retinal Vessel Density and Retinal Nerve Fiber Layer Thickness: A Prospective Study of One-Year Follow-Up of Patients with Parkinson’s Disease

References

• Peng H, Chen S, Wu S, et al. Alpha-synuclein in skin as a high-quality biomarker for Parkinson’s disease. J Neurol Sci. 2023;451:120730. doi:10.1016/j.jns.2023.120730
   PubMed Web of Science ®Google Scholar
• Nicoletti A, Luca A, Baschi R, et al. Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study. J Neurol. 2021;268(2):549–558. doi:10.1007/s00415-020-10189-8
   PubMed Web of Science ®Google Scholar
• Kummer BR, Diaz I, Wu X, et al. Associations between cerebrovascular risk factors and Parkinson disease. Ann Neurol. 2019;86(4):572–581. doi:10.1002/ana.25564
   PubMed Web of Science ®Google Scholar
• Liu Y, Xue L, Zhang Y, Xie A. Association between stroke and Parkinson’s disease: a meta-analysis. J Mol Neurosci. 2020;70(8):1169–1176. doi:10.1007/s12031-020-01524-9
   PubMed Web of Science ®Google Scholar
• Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophth Vis Sci. 2000;41:1217–1228.
   PubMed Web of Science ®Google Scholar
• London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9(1):44–53. doi:10.1038/nrneurol.2012.227
   PubMed Web of Science ®Google Scholar
• Lyu J, Mu X. Genetic control of retinal ganglion cell genesis. Cell Mol Life Sci. 2021;78:4417–4433. RGC的发生. doi:10.1007/s00018-021-03814-w
   PubMed Web of Science ®Google Scholar
• Benhar I, Ding J, Yan W, et al. Temporal single-cell atlas of non-neuronal retinal cells reveals dynamic, coordinated multicellular responses to central nervous system injury. Nat Immunol. 2023;24:700–713. doi:10.1038/s41590-023-01437-w
   PubMed Web of Science ®Google Scholar
• Chalkias I, Tegos T, Topouzis F, Tsolaki M. Ocular biomarkers and their role in the early diagnosis of neurocognitive disorders. Eur J Ophthalmol. 2021;31:2808–2817. doi:10.1177/11206721211016311
   PubMed Web of Science ®Google Scholar
• Garzone D, Finger RP, Mauschitz MM, et al. Visual impairment and retinal and brain neurodegeneration: a population-based study. Hum Brain Mapp. 2023;44:2701–2711. doi:10.1002/hbm.26237
   PubMed Web of Science ®Google Scholar
• Cole ED, Moult EM, Dang S, et al. The definition, rationale, and effects of thresholding in OCT angiography. Ophthalmol Retina. 2017;1:435–447. doi:10.1016/j.oret.2017.01.019
   PubMedGoogle Scholar
• Lains I, Wang JC, Cui Y, et al. Retinal applications of swept source optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA). Prog Retin Eye Res. 2021;84:100951. doi:10.1016/j.preteyeres.2021.100951
   PubMed Web of Science ®Google Scholar
• Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–2653. doi:10.1002/mds.23429
   PubMed Web of Science ®Google Scholar
• Liu J. Diagnostic criteria for Parkinson’s disease in China (2016). Chin J Neurol. 2016;49(4):268–271.
   Google Scholar
• Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170. doi:10.1002/mds.22340
   PubMed Web of Science ®Google Scholar
• Tewarie P, Balk L, Costello F, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One. 2012;7(4):e34823. doi:10.1371/journal.pone.0034823
   PubMed Web of Science ®Google Scholar
• Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):459–480. doi:10.1016/S1474-4422(18)30499-X
   PubMed Web of Science ®Google Scholar
• Qi S, Yin P, Wang L, et al. Prevalence of Parkinson’s disease: a community‐based study in China. Mov Disord. 2021;36(12):2940–2944. doi:10.1002/mds.28762
   PubMed Web of Science ®Google Scholar
• Normando EM, Davis BM, De Groef L, et al. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta Neuropathol Commun. 2016;4(1):86. doi:10.1186/s40478-016-0346-z
   PubMedGoogle Scholar
• Veys L, Vandenabeele M, Ortuño-Lizarán I, et al. Retinal α-synuclein deposits in Parkinson’s disease patients and animal models. Acta Neuropathol. 2019;137(3):379–395. doi:10.1007/s00401-018-01956-z
   PubMed Web of Science ®Google Scholar
• Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S. α-synuclein in the inner retina in Parkinson disease. Ann Neurol. 2014;75(6):964–966. doi:10.1002/ana.24182
   PubMed Web of Science ®Google Scholar
• Guo L, Normando EM, Shah PA, De Groef L, Cordeiro MF. Oculo-visual abnormalities in Parkinson’s disease: possible value as biomarkers. Mov Disord. 2018;33(9):1390–1406. doi:10.1002/mds.27454
   PubMed Web of Science ®Google Scholar
• Xiao RQ, Ying W, Zhenguo L. Circadian rhythm disorder of blood pressure in Parkinson′s disease. Chin J Neurol. 2021;54(12):1307–1311.
   Google Scholar
• Huang F, Shu Z, Huang Q, et al. Retinal dopamine D2 receptors participate in the development of myopia in mice. Invest Opthalmol Vis Sci. 2022;63(1):24. doi:10.1167/iovs.63.1.24
   Web of Science ®Google Scholar
• Marrocco E, Indrieri A, Esposito F, et al. α-synuclein overexpression in the retina leads to vision impairment and degeneration of dopaminergic amacrine cells. Sci Rep. 2020;10(1):9616. doi:10.1038/s41598-020-66497-6
   PubMed Web of Science ®Google Scholar
• Rascunà C, Cicero CE, Chisari CG, et al. Retinal thickness and microvascular pathway in idiopathic rapid eye movement sleep behaviour disorder and Parkinson’s disease. Parkinsonism Relat Disord. 2021;88:40–45. doi:10.1016/j.parkreldis.2021.05.031
   PubMed Web of Science ®Google Scholar
• La Morgia C, Di Vito L, Carelli V, Carbonelli M. Patterns of retinal ganglion cell damage in neurodegenerative disorders: parvocellular vs magnocellular degeneration in optical coherence tomography studies. Front Neurol. 2017;8:710. doi:10.3389/fneur.2017.00710
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang D, Ji J, Wang Y, Zhang R. Central retina changes in Parkinson’s disease: a systematic review and meta-analysis. J Neurol. 2021;268(12):4646–4654. doi:10.1007/s00415-020-10304-9
   PubMed Web of Science ®Google Scholar
• Sen A, Tugcu B, Coskun C, Ekinci C, Nacaroglu SA. Effects of levodopa on retina in Parkinson disease. Eur J Ophthalmol. 2014;24(1):114–119. doi:10.5301/ejo.5000338
   PubMed Web of Science ®Google Scholar
• Yin Z, Weixia D. Changes of retina I nerve fiber layer thick ness and its correlation with visuaI field mean defects in early Parkinson’s disease. Chin J Ocul Fundus Di. 2010;4:339–342.
   Google Scholar
• Kassavetis P, Kaski D, Anderson T, Hallett M. Eye Movement disorders in movement disorders. Mov Disord Clin Pract. 2022;9(3):284–295. doi:10.1002/mdc3.13413
   PubMed Web of Science ®Google Scholar
• Atum M, Demiryürek BE. Retinal morphological changes during the two years of follow-up in Parkinson’s disease. Ideggyogy Sz. 2021;74(1–2):57. doi:10.18071/isz.74.0057
   PubMedGoogle Scholar
• Abd Hamid MR, Wan Hitam W, Abd Halim S. Retinal nerve fiber layer and macular thickness in Parkinson’s disease patients. Cureus. 2021;13(7):e16224. doi:10.7759/cureus.16224
   PubMed Web of Science ®Google Scholar
• Hasanov S, Demirkilinc Biler E, Acarer A, Akkın C, Colakoglu Z, Uretmen O. Functional and morphological assessment of ocular structures and follow-up of patients with early-stage Parkinson’s disease. Int Ophthalmol. 2019;39(6):1255–1262. doi:10.1007/s10792-018-0934-y
   PubMed Web of Science ®Google Scholar
• Jiménez B, Ascaso FJ, Cristóbal JA, López Del Val J. Development of a prediction formula of Parkinson disease severity by optical coherence tomography. Mov Disord. 2014;29(1):68–74. doi:10.1002/mds.25747
   PubMed Web of Science ®Google Scholar
• Ma L, Xu L, Mao C, et al. Progressive changes in the retinal structure of patients with Parkinson’s disease. J Parkinsons Dis. 2018;8(1):85–92. doi:10.3233/JPD-171184
   PubMedGoogle Scholar
• Satue M, Seral M, Otin S, et al. Retinal thinning and correlation with functional disability in patients with Parkinson’s disease. Br J Ophthalmol. 2014;98(3):350–355. doi:10.1136/bjophthalmol-2013-304152
   PubMed Web of Science ®Google Scholar
• Satue M, Rodrigo MJ, Obis J, et al. Evaluation of progressive visual dysfunction and retinal degeneration in patients with Parkinson’s disease. Invest Ophthalmol Vis Sci. 2017;58(2):1151–1157. doi:10.1167/iovs.16-20460
   PubMed Web of Science ®Google Scholar
• Pierzchlińska A, Kwaśniak-Butowska M, Sławek J, Droździk M, Białecka M. Arterial blood pressure variability and other vascular factors contribution to the cognitive decline in Parkinson’s disease. Molecules. 2021;26(6):1523. doi:10.3390/molecules26061523
   PubMed Web of Science ®Google Scholar
• Zhang X, Xiao H, Liu C, et al. Optical coherence tomography angiography reveals distinct retinal structural and microvascular abnormalities in cerebrovascular disease. Front Neurosci. 2020;14:588515. doi:10.3389/fnins.2020.588515
   PubMed Web of Science ®Google Scholar
• Robbins CB, Thompson AC, Bhullar PK, et al. Characterization of retinal microvascular and choroidal structural changes in Parkinson disease. JAMA Ophthalmol. 2021;139(2):182. doi:10.1001/jamaophthalmol.2020.5730
   PubMed Web of Science ®Google Scholar
• Shi C, Chen Y, Kwapong WR, et al. Characterization by fractal dimension analysis of the retinal capillary network in Parkinson disease. Retina. 2020;40(8):1483–1491. doi:10.1097/IAE.0000000000002641
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang D, Gao Y, et al. Retinal flow density changes in early-stage Parkinson’s disease investigated by swept-source optical coherence tomography angiography. Curr Eye Res. 2021;46(12):1886–1891. doi:10.1080/02713683.2021.1933054
   PubMed Web of Science ®Google Scholar
• Kwapong WR, Ye H, Peng C, et al. Retinal microvascular impairment in the early stages of Parkinson’s Disease. Invest Ophthalmol Vis Sci. 2018;59(10):4115–4122. doi:10.1167/iovs.17-23230
   PubMed Web of Science ®Google Scholar
• Zou J, Liu K, Li F, Xu Y, Shen L, Xu H. Combination of optical coherence tomography (OCT) and OCT angiography increases diagnostic efficacy of Parkinson’s disease. Quant Imaging Med Surg. 2020;10(10):1930–1939. doi:10.21037/qims-20-460
   PubMed Web of Science ®Google Scholar
• Deng Y, Jie C, Wang J, Liu Z, Li Y, Hou X. Evaluation of retina and microvascular changes in the patient with Parkinson’s disease: a systematic review and meta-analysis. Front Med. 2022;9:957700. doi:10.3389/fmed.2022.957700
   Web of Science ®Google Scholar
• Miri S, Shrier EM, Glazman S, et al. The avascular zone and neuronal remodeling of the fovea in Parkinson disease. Ann Clin Transl Neurol. 2015;2(2):196–201. doi:10.1002/acn3.146
   PubMed Web of Science ®Google Scholar
• Elabi O, Gaceb A, Carlsson R, et al. Human α-synuclein overexpression in a mouse model of Parkinson’s disease leads to vascular pathology, blood brain barrier leakage and pericyte activation. Sci Rep. 2021;11(1):1120.
   PubMed Web of Science ®Google Scholar
• Ouellette J, Lacoste B. From neurodevelopmental to neurodegenerative disorders: the vascular continuum. Front Aging Neurosci. 2021;13:749026.
   PubMed Web of Science ®Google Scholar
• Xue C, Li X, Ba L, et al. MSC-derived exosomes can enhance the angiogenesis of human brain MECs and show therapeutic potential in a mouse model of Parkinson’s disease. Aging Dis. 2021;12(5):1211. doi:10.14336/AD.2020.1221
   PubMed Web of Science ®Google Scholar